Unknown

Dataset Information

0

A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.


ABSTRACT: Recent West African Ebola virus (EBOV) epidemics have led to testing different anti-EBOV vaccines, including a replication-defective adenovirus (RD-Ad) vector (ChAd3-EBOV) and an infectious, replication-competent recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (rVSV-EBOV; also known as rVSV-ZEBOV). While RD-Ads elicit protection, when scaled up to human trials, the level of protection may be much lower than that of vaccines containing viruses that can replicate. Although a replication-competent Ad (RC-Ad) vaccine might generate a level of protection approximating that of rVSV, this infectious vector would also risk causing adenovirus disease. We recently described a "single-cycle" adenovirus (SC-Ad) vector that amplifies antigen genes like RC-Ad, but that avoids the risk of adenovirus infection. Here we have tested an SC-Ad6 vector expressing the glycoprotein (GP) from a 2014 EBOV strain in mice, hamsters, and rhesus macaques. We show that SC-Ad6-EBOV GP induces a high level of serum antibodies in all species and mediates significant protection against pseudo-challenge with rVSV-EBOV expressing luciferase in mice and hamsters. These data suggest that SC-Ad6-EBOV GP may be useful during future EBOV outbreaks.

SUBMITTER: Anguiano-Zarate SS 

PROVIDER: S-EPMC6217725 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.

Anguiano-Zarate Stephanie S SS   Matchett William E WE   Nehete Pramod N PN   Sastry Jagannadha K JK   Marzi Andrea A   Barry Michael A MA  

The Journal of infectious diseases 20181101 12


Recent West African Ebola virus (EBOV) epidemics have led to testing different anti-EBOV vaccines, including a replication-defective adenovirus (RD-Ad) vector (ChAd3-EBOV) and an infectious, replication-competent recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (rVSV-EBOV; also known as rVSV-ZEBOV). While RD-Ads elicit protection, when scaled up to human trials, the level of protection may be much lower than that of vaccines containing viruses that can replicate. Although  ...[more]

Similar Datasets

| S-EPMC7564163 | biostudies-literature
| S-EPMC3153429 | biostudies-literature
| S-EPMC2669164 | biostudies-literature
| S-EPMC7158672 | biostudies-literature
| S-EPMC8051823 | biostudies-literature
| S-EPMC2720404 | biostudies-literature
| S-EPMC2849326 | biostudies-literature
| S-EPMC1459482 | biostudies-literature
| S-EPMC4564535 | biostudies-literature
| S-EPMC2704787 | biostudies-literature